Brief: Alpine Immune Sciences And Horizon Therapeutics PLC Announce Exclusive License And Collaboration DEAL
Dec 16 (Reuters) - Horizon Therapeutics PLC HZNP.O :
* ALPINE IMMUNE SCIENCES AND HORIZON THERAPEUTICS PLC
ANNOUNCE
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT TO DEVELOP NOVEL
PROTEIN-BASED THERAPIES FOR AUTOIMMUNE AND INFLAMMATORY DISEASES
Source text for Eikon: ID:nBw7TxTSra
Further company coverage: HZNP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpine Immune Sciences
See all newsAlpine Immune Sciences Inc reports results for the quarter ended in January - Earnings Summary
Brief: Alpine Immune Sciences Q1 EPS USD -0.28 Vs. IBES Estimate USD -0.41
Moves: Lazard hires veteran healthcare dealmaker Colocci as vice chairman
U.S. RESEARCH ROUNDUP-Cheesecake Factory, Netflix, Texas Roadhouse
US STOCKS-S&P 500, Nasdaq end sharply higher on soft inflation data, eyes on earnings